Literature DB >> 7813744

Monoaminergic regulation of neuroendocrine function and its modification by cocaine.

A D Levy1, M H Baumann, L D Van de Kar.   

Abstract

Neuroendocrine pharmacology represents a potentially valuable approach to the assessment of alterations in neuronal function in the brain of human cocaine abusers. Neuroendocrine effects of the monoamine uptake inhibitor cocaine have predominantly been examined in laboratory animals. These preclinical studies may help to identify the optimal challenge tests to be performed in clinical studies. In laboratory animals, acute administration of cocaine activates the hypothalamic-pituitary-adrenal axis, via actions on serotonergic and dopaminergic neurons in the brain. Cocaine also reduces prolactin secretion, probably by dopaminergic mechanisms, although the necessary studies to confirm this hypothesis have not been performed. Cocaine also reduces renin secretion, and increases vasopressin and luteinizing hormone secretion, by mechanisms which have not been clearly established. The adrenocorticotropin, corticosterone, prolactin, and renin responses to cocaine are generally unaltered by prior cocaine exposure, suggesting that tolerance or sensitization to the endocrine effects of cocaine does not occur. However, several studies have determined that prior cocaine exposure alters the serotonergic regulation of hormone secretion. Chronic cocaine exposure reduces some of the hormone responses to the serotonin (5-HT) releasers p-chloroamphetamine and d-fenfluramine, suggesting deficits in the functional status of serotonergic nerve terminals. Additionally, repeated cocaine exposure produces subsensitive 5-HT1A-mediated hormone responses, and supersensitive 5-HT2-mediated responses. Alterations in dopaminergic- or noradrenergic-mediated hormone responses have not been examined in animals chronically exposed to cocaine. Endocrine studies in human cocaine abusers have largely examined basal hormone levels or the hormone responses to cocaine. Strong conclusions from these studies are limited because (1) many neuronal and nonneuronal systems regulate secretion of each hormone, so that alterations in basal hormone levels cannot be attributed to only one neurotransmitter; and (2) hormone responses to cocaine cannot be examined in cocaine-naive subjects due to ethical considerations, making it impossible to determine whether the response in cocaine abusers is abnormal. It may be more beneficial for studies in cocaine abusers to examine the hormone responses to drugs that specifically affect monoaminergic neurons and compare the data with cocaine-naive individuals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7813744     DOI: 10.1006/frne.1994.1006

Source DB:  PubMed          Journal:  Front Neuroendocrinol        ISSN: 0091-3022            Impact factor:   8.606


  11 in total

1.  Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.

Authors:  J K Staley; Q Ouyang; J Pablo; W L Hearn; D D Flynn; R B Rothman; K C Rice; D C Mash
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

Review 2.  Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions.

Authors:  Richard B Rothman; Bruce E Blough; Michael H Baumann
Journal:  AAPS J       Date:  2007-01-05       Impact factor: 4.009

Review 3.  Estrogen control of central neurotransmission: effect on mood, mental state, and memory.

Authors:  G Fink; B E Sumner; R Rosie; O Grace; J P Quinn
Journal:  Cell Mol Neurobiol       Date:  1996-06       Impact factor: 5.046

Review 4.  Behavioral characteristics and neurobiological substrates shared by Pavlovian sign-tracking and drug abuse.

Authors:  Arthur Tomie; Kathryn L Grimes; Larissa A Pohorecky
Journal:  Brain Res Rev       Date:  2007-12-28

Review 5.  3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.

Authors:  Michael H Baumann; Xiaoying Wang; Richard B Rothman
Journal:  Psychopharmacology (Berl)       Date:  2006-03-16       Impact factor: 4.530

6.  Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats.

Authors:  M H Baumann; M A Ayestas; R B Rothman
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

7.  Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA).

Authors:  Michael H Baumann; Richard B Rothman
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

8.  Individual differences in amphetamine sensitization, behavior and central monoamines.

Authors:  Jamie L Scholl; Na Feng; Michael J Watt; Kenneth J Renner; Gina L Forster
Journal:  Physiol Behav       Date:  2008-12-07

9.  Relationship of serum prolactin with severity of drug use and treatment outcome in cocaine dependence.

Authors:  Ashwin A Patkar; Paolo Mannelli; Kenneth M Certa; Kathleen Peindl; Heather Murray; Michael J Vergare; Wade H Berrettini
Journal:  Psychopharmacology (Berl)       Date:  2004-04-03       Impact factor: 4.530

10.  Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges.

Authors:  M H Baumann; R D Clark; F H Franken; J J Rutter; R B Rothman
Journal:  Neuroscience       Date:  2008-01-12       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.